AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05507645
Drug: Recombinant Human Prourokinase for Injection (rhPro-UK)
RxNorm normalized name: hyaluronidase, human recombinant Injection
DrugBank: Urokinase (DB00013)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15mg of rhPro-UK intravenous bolus within 3 minutes, and the remaining 20mg intravenous drip within 30 minutes.
Trial: NCT04890106
Drug: Test - Bimatoprost 0.01% Ophthalmic Solution
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subjects in one arm will receive one drop of the test drug in both the eyes every evening at approximately 10:00 pm ± 2 hours for 42 days.
Trial: NCT05453448
Drug: tenofovir alafenamide
RxNorm normalized name: Tenofovir Alafenamide
DrugBank: Tenofovir alafenamide (DB09299)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Antiviral therapy
Trial: NCT05453448
Drug: Entecavir
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: entecavir
Trial: NCT04796025
Drug: Sintilimab; Bevacizumab Biosimilar
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1-4 cycles, intra-arterial infusion: sindilimab 200mg + bevacizumab 7.5mg/kg, q3w; 5-18 cycles: Sintilimab (200mg ivdrip D1 Q3W)+Bevacizumab Biosimilar (15mg/kg ivdrip D1 Q3W）
Trial: NCT04839536
Drug: Sevoflurane inhalant product
RxNorm normalized name: sevoflurane Inhalant Product
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevoflurane will be delivered in an incremental dose to throughout procedure to achieve clinical sedation endpoint OAAS 3.
Trial: NCT02571608
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The study intervention involves Type II Diabetes Mellitus patient self-administered metformin vs. placebo according to regular dosing schedule and randomization. Both placebo and active drug will be over-encapsulated by pharmacy so that they will be indistinguishable to the personnel involved in the study.
Trial: NCT05446623
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Opioid free anesthesia (OFA) consists in the simultaneous administration of alpha2-agonist (for example the dexmedetomidine), sodium channel blocker (lidocaine), and NMDA antagonists receptors (Ketamine). Its aim is to control de cardiovascular nociceptive response to the surgical stimulation.
Trial: NCT05316493
Drug: Megestrol Acetate 160 MG Oral Tablet
RxNorm normalized name: megestrol acetate 160 MG Oral Tablet
DrugBank: Megestrol acetate (DB00351)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: enrolled participants will take Megestrol Acetate 160mg daily
Trial: NCT05316493
Drug: Levonorgestrel-Releasing Intrauterine Contraceptive System (Mirena), 52 Mg
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: enrolled patients will be treated with LNG-IUS.
Trial: NCT00438789
Drug: eculizumab
RxNorm normalized name: Eculizumab
DrugBank: Eculizumab (DB01257)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 600mg IV every week and 900mg IV every 2 weeks
Trial: NCT05195645
Drug: Abatacept 250 MG
RxNorm normalized name: abatacept 250 MG
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Abatacept will be administered by intravenous injection over 1h15 to 2h30 on D1, D5+/-2 and D14+/-2 at 10mg/kg (arm A), or 20mg/kg (arm B) or 25mg/kg (arm C) depending on the randomization (max 3 000 mg per administration). Starting Day 21 (after evaluation of the primary outcome), other injection of abatacept may be given (D22 at D90) with dosage (10 or 20mg/kg max) decided by the treating physician (max 2 500 mg per administration) as a function of the relapse or not of the ICI myocarditis after immunosuppressant therapeutics tapering. After day 21, the administrations will be carried out in open but the blind administration 1 to 3 (D1 to D21) will be kept.
Trial: NCT06351891
Drug: 14-day bismuth quadruple regimen containing cefuroxime and levofloxacin
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 14-day bismuth quadruple regimen containing cefuroxime and levofloxacin:Tegoprazan 50mg bid, Bismuth potassium citrate capsules 0.6g bid,Cefuroxime tablets 500mg bid,Levofloxacin 500mg qd,14 days.
Trial: NCT05340790
Drug: Dose 1 to 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories
RxNorm normalized name: afamelanotide
DrugBank: Afamelanotide (DB04931)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Escalating doses of 1 mg (0.1%)、2.5mg (0.25%)、5 mg (0.5%)、10mg (1%)、15 mg (1.5%)；single dose administration；topical vaginal suppository ；multiple-dose administration after single dose administration a 3-day wash out period ; once-daily for 6 consecutive days;
Trial: NCT05340790
Drug: Placebo dose 1 to 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories
RxNorm normalized name: afamelanotide
DrugBank: Afamelanotide (DB04931)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dose 1、2、3、4 and 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories respective placebos；single dose administration；topical vaginal suppository ；multiple-dose administration after single dose administration a 3-day wash out period ; once-daily for 6 consecutive days;
Trial: NCT06186986
Drug: Brentuximab vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5 Participants will receive unlabeled brentuximab and 20 participants will receive 89ZR-Brentuximab.
Trial: NCT06648772
Drug: Roflumilast Cream 0.3%
DrugBank: Roflumilast (DB01656)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Roflumilast Cream 0.3%
Trial: NCT03098225
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone pulse therapy for 12 weeks as follows: 500 mg IV once weekly for 6 weeks, then 250 mg IV once weekly for a further 6 weeks. Cumulative dose 4.5 g.
Trial: NCT04599465
Drug: IVA
RxNorm normalized name: Viva
DrugBank: Adenosine (DB00640)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets for oral administration.
Trial: NCT04647084
Drug: Lidocaine 2% Injectable Solution
RxNorm normalized name: lidocaine 2% injectable solution
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An elastic band will be placed around the subject's arm, and the elastic band will be removed once the IV is inserted. After the elastic band is placed on the subject's arm, the arm will be cleaned, and then a small skin wheel will be created with the lidocaine that will be injected very close to where the IV will be placed. The IV will be placed within about a minute from the time when the lidocaine was injected.
Trial: NCT00073203
Drug: Placebo and Paroxetine
DrugBank: Paroxetine (DB00715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05767827
Drug: ropivacaine, lidocaine with adrenaline
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group R includes 0.35% ropivacaine 20ml, 1.5 % lidocaine with adrenaline 10ml
Trial: NCT05767827
Drug: Dexmedetomidine, ropivacaine, lidocaine with adrenaline
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 1mcg/kg and 0.35% ropivacaine with normal saline (20ml), 1.5% lidocaine with adrenaline (10ml) in group RD
Trial: NCT00445250
Drug: Calcipotriol
RxNorm normalized name: Calcipotriol
DrugBank: Calcipotriol (DB02300)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06464263
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: to investigate the postoperative analgesic-sedative effect of dexmedetomidine versus fentanyl-midazolam to achieve fast-track extubation after adult valvular cardiac surgeries.
Trial: NCT05464368
Drug: 18F-MK6240
RxNorm normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18F-MK6240 is an investigational PET radiotracer discovered by Merck Research Laboratories and is being developed by Cerveau Technologies, Inc.,for imaging neurofibrillary tangles (NFTs)in the brains of people withAlzheimerdisease.18F-MK6240 has been reported to exhibit good kinetics with high binding levels to brain regions associated with deposition of neurofibrillary tangles in people with AD(35,36).The tracer has been used to monitor the progression of AD.The injected activity for18F-MK6240 will be as low as practicable, while still allowing accurate quantification of the PET images.The injected dose will be 185MBq(5mCi) has been selected based on the radiation dose estimates gathered in human subjects(37)and in accordance with the principle that radiation doses should be as low as reasonably achievable.~This radiotracer will be manufactured on site in the Mallinckrodt Institute of Radiology Cyclotron Facility, a certified Nuclear Pharmacy.
Trial: NCT05464368
Drug: 18F-GTP1
RxNorm normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18F-GTP1is anInvestigational tau PET radiotracer being developed by Genentech for imaging intraneuronal neurofibrillary tangles in patients with AlzheimerDisease. 18F-GTP1 has been reported to exhibit high affinity and selectively for tau pathology, favorable dosimetry and brain kinetics. Degree of 18F-GTP1-specific binding increased withAD severity, could differentiate diagnostic cohorts, and monitor longitudinal change in tau burden.~18F-GTP1 will be provided from LMI sourced through Illinois or New Jersey certified location.
Trial: NCT05064397
Drug: Eptinezumab
RxNorm normalized name: Eptinezumab
DrugBank: Eptinezumab (DB14040)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eptinezumab will be administered per schedule specified in the arm description.
Trial: NCT05987956
Drug: Alectinib - Usual
DrugBank: Alectinib (DB11363)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Usual Alectinib Chemotherapy (NDC...01)~- ALECENSA - alectinib hydrochloride capsule -- 600 mg orally twice daily
Trial: NCT05987956
Drug: Alectinib - Study
DrugBank: Alectinib (DB11363)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Study Alectinib Chemotherapy (NDC...86)~- ALECENSA - alectinib hydrochloride capsule -- 600 mg orally twice daily
Trial: NCT06409845
Drug: Eptinezumab 100 or 300 mg ev
RxNorm normalized name: Eptinezumab
DrugBank: Eptinezumab (DB14040)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients administered eptinezumab 100 or 300 mg ev quarterly for migraine prevention
Trial: NCT04799353
Drug: Budigalimab
RxNorm normalized name: Budigalimab
DrugBank: Budigalimab (DB16668)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC)
Trial: NCT04799353
Drug: Budigalimab
RxNorm normalized name: Budigalimab
DrugBank: Budigalimab (DB16668)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV)
Trial: NCT00043212
Drug: Dendritic cell immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05112081
Drug: Botulinum toxin type A
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: The group will receive a solution of 100 units BTX with 10 ml sterile saline close to the superficial inguinal ring.
Trial: NCT04985669
Drug: Prucalopride 2mg
RxNorm normalized name: PRUCALOPRIDE 2MG TAB
DrugBank: Prucalopride (DB06480)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: one group of patient will receive prucalopride once daily one group of patient will receive lubiprostone twice daily
Trial: NCT05348239
Drug: Sodium Copper Chlorophyllin
RxNorm normalized name: sodium copper chlorophyllin
DrugBank: Sodium copper chlorophyllin (DB16522)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium-copper-chlorophyllin (CHL) is a phytopharmaceutical drug obtained from green plant pigment, chlorophyll. Chlorophyllin scavenges radiation-induced free radicals and reactive oxygen species. It is used as a food colorant and OTC in the USA, Japan, Australia and China for many years for a variety of health benefits including prevention of body odour in geriatric patients, enhanced wound healing, antibacterial action, prevention of cancer in the high-risk populations exposed to hepatocarcinogen aflatoxin B1, treatment of faecal incontinence etc. Studies have shown that CHL has immunostimulatory, anti-inflammatory and antiviral effects in addition to antioxidant and radioprotective properties. It increases the expression of a transcription factor (protein) Nrf2 which improves lymphocyte survival and enables efficient detoxification after exposure to radiation. The duration of therapy will be up to 6 months depending upon the response of participants.
Trial: NCT06003153
Drug: oral semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Semaglutide is the only oral glucagon-like peptide 1 receptor agonist (GLP-1 RA) approved for treatment of type 2 diabetes. Participants will receive 7 mg of oral semaglutide once daily for 14 days in between Visit 1 and Visit 2.
Trial: NCT05561387
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given SC
Trial: NCT05561387
Drug: Daratumumab and Hyaluronidase-fihj
RxNorm normalized name: daratumumab-fihj / hyaluronidase-fihj Injection
DrugBank: Hyaluronidase (ovine) (DB00070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given SC
Trial: NCT05561387
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT05561387
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT05688488
Drug: Curcumin
RxNorm normalized name: Curcumin
DrugBank: Curcumin (DB11672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin was applied to both wound sites of bilateral vocal cords. After evenly applied, gently massage the applied site for 3-5 minutes until the drug was fully absorbed.
Trial: NCT05688488
Drug: Mitomycin-C
RxNorm normalized name: Mitomycin-C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin-C was applied to both wound sites of bilateral vocal cords. After evenly applied, gently massage the applied site for 3-5 minutes until the drug was fully absorbed.
Trial: NCT02961491
Drug: Ultratrace Iobenguane I131
RxNorm normalized name: Iodohippurate sodium I131
DrugBank: Iobenguane (DB06704)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive a dosimetry dose of AZEDRA and will undergo 3 whole body scans. If the scans indicate tumor avidity for AZEDRA, the subjects will receive up to 2 therapeutic doses of AZEDRA each at 500 mCi (or 8 mCi/kg, for subjects weighing 62.5 kg or less) approximately 90 days apart.
Trial: NCT06195189
Drug: Sunvozertinib
RxNorm normalized name: Sunvozertinib
DrugBank: Sunvozertinib (DB18925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunvozertinib 200mg Quaquedie (QD)
Trial: NCT03085186
Drug: Crizotinib
RxNorm normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT05271331
Drug: ESP block with saline
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bilateral ultrasound guided injection of saline in the erector spinae plane (below erector spinae plane muscle group and above the transverse process of the vertebra)
Trial: NCT05271331
Drug: Wound infiltration with saline
RxNorm normalized name: Simply Saline Wound Wash
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Blinded injection of saline in the skin, subcutaneous tissue and muscles at the site of surgical incision
Trial: NCT05271331
Drug: ESP block with local anesthetic
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bilateral ultrasound guided injection of local anesthetic (ropivacaine 0.35%, 40ml) in the erector spinae plane (below erector spinae plane muscle group and above the tranverse process of the vertebra)
Trial: NCT04751877
Drug: Isatuximab
RxNorm normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Isatuximab by IV route, per 28 days cycle - Cycle1: 10 mg/kg on days 1, 8, 15, and 22. Cycles 2 to 12: 10 mg/kg on days 1 and 15. From cycle 13: 10 mg/kg on day 1.
Trial: NCT04751877
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide by oral route, per 28 days cycle - 25 mg daily on days 1-21.
Trial: NCT04751877
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib sub-cutaneous, per 28 days cycle - Cycles 1 to 12: 1.3 mg/m2 on days 1, 8, 15. Cycles 13-18: 1.3 mg/m2 on days 1, 15.
Trial: NCT04751877
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone by oral route, per 28 days cycle - 20 mg daily on days 1, 8, 15 and 22.
Trial: NCT00002148
Drug: OPC 14117
RxNorm normalized name: OPC-14523
DrugBank: OPC-14523 (DB05422)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04903795
Drug: hEGFRvIII-CD3 (BRiTE)
RxNorm normalized name: Muromonab-Cd3
DrugBank: Muromonab (DB00075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bispecific T cell engager possessing one effector binding arm specific for the epsilon subunit of CD3 (a signaling molecule complex associated with the T cell receptor on T cells) while the opposing target-binding arm is directed against the hEGFRvIII epitope that is differentially expressed on the surface of tumor cells
Trial: NCT05630885
Drug: CVC 150 mg
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as one 150-mg tablet by mouth once a day with food.
Trial: NCT05630885
Drug: CVC 300 mg
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as two 150-mg tablets by mouth once a day with food.
Trial: NCT05189028
Drug: gemcitabine and cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Neoadjuvant chemotherapy:gemcitabine and cisplatin
Trial: NCT06488586
Drug: Low dose IV Ketamine vs. IN Esketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For IV ketamine treatment, ketamine is administered at 0.5mg/kg over 40 minutes. For IN esketamine treatment, esketamine is administered as a nasal spray, two sprays per nostril (56mg total) for the first treatment and three sprays per nostril (84mg) for the rest of the acute series. All treatments are administered at the academic center under the supervision of a mental health care professional. Patients are asked to come fasting at least two hours prior to treatment and to remain resting in the treatment room throughout the dosing session. Throughout each dosing session, blood pressure, oxygen levels, and onset, duration and severity of common side effects are recorded by nursing staff and/or physicians. Patients are discharged after a minimum of 30 minutes post administration, provided that the vital signs return to baseline and that the patient is calm, alert, and oriented.
Trial: NCT05698901
Drug: Agalsidase beta
RxNorm normalized name: Agalsidase beta
DrugBank: Agalsidase beta (DB00103)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The treatment is following local reimbursement criteria and judge by physician
Trial: NCT05596786
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: One course of IV rituximab consisting of a first infusion of 1000 mg (500 mL solution) rituximab (day 1), and a second infusion of 1000 mg (500 mL solution) rituximab two weeks later (day 15)
Trial: NCT04922034
Drug: Amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Outcome of patients with negative oral challenge to amoxicillin
Trial: NCT00001000
Drug: Ampligen
DrugBank: Rintatolimod (DB16425)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06368492
Drug: Psilocybin
RxNorm normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each participant will receive 2 different doses of psilocybin (5mg and 10mg) and a matching placebo on three separate occasions.
Trial: NCT05553184
Drug: Formoterol Fumarate 12 micrograms Inhalation Powder
RxNorm normalized name: formoterol
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: At time 60 minutes, a total of 48 micrograms will be inhaled within 3 minutes: 4 inhalations of 12 micrograms of fumarate formoterol (Oxeze® Turbuhaler®).
Trial: NCT01784718
Drug: Buphenyl
RxNorm normalized name: Buphenyl
DrugBank: Phenylbutyric acid (DB06819)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04849715
Drug: parsaclisib
RxNorm normalized name: Parsaclisib
DrugBank: Parsaclisib (DB14867)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: parsaclisib will be administered orally once daily.
Trial: NCT04849715
Drug: rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: rituximab is administered IV on Day 1 of each 28-day cycle for 6 cycles.
Trial: NCT04849715
Drug: bendamustine
RxNorm normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: bendamustine is administered IV on Day 1 and 2 of each 28-day cycle for 6 cycles.
Trial: NCT06197763
Drug: Colesevelam
RxNorm normalized name: Colesevelam
DrugBank: Colesevelam (DB00930)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 625 mg tablets - 3 tables twice per day of Colesevelam or placebo for 6 weeks (crossover), interspersed by 8 week of washout time.
Trial: NCT05387668
Drug: BGB-23339
RxNorm normalized name: BGB-DXP593
DrugBank: BGB-DXP593 (DB16357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally as a tablet.
Trial: NCT05047848
Drug: Chidamide
RxNorm normalized name: Chidamide
DrugBank: Tucidinostat (DB06334)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: chidamide 30mg orally，Biw